April 13, 2021

glimworm

Advances in world technology

Okyo Pharma Restricted (LSE:OKYO) | RNS | OKYO Pharma Constrained

NOT FOR Launch, PUBLICATION OR DISTRIBUTION, IN Full OR IN Portion, IN OR INTO OR FROM ANY JURISDICTION The place TO DO SO WOULD Represent A VIOLATION OF THE Appropriate Regulations OF This sort of JURISDICTION

THIS ANNOUNCEMENT Incorporates Within Information and facts FOR THE Reasons OF Report 7 OF REGULATION (EU) NO 596/2014

 

OKYO Pharma Limited

(“OKYO” or the “Enterprise”)

OKYO announces filing of a patent application covering the use of Chemerin and connected analogues to handle “cytokine storm” related with COVID-19 and ARDS

 

London and Boston, MA, January 19, 2021 – OKYO (LSE: OKYO OTCQB: EMMLF), the life sciences and biotechnology company targeted on the discovery and enhancement of novel molecules to treat inflammatory dry eye health conditions and serious suffering, announces that it has these days submitted a patent application for the likely use of chemerin and chemerin analogues for prophylaxis against and cure of indications involved with, or resulting from, infection with SARS-CoV-2 virus, including irritation because of to the cytokine storm brought on by COVID-19 ailment (“COVID-19”), and acute respiratory distress syndrome (“ARDS”).

OKYO has been creating the chemerin molecule as a promising anti-inflammatory procedure for dry-eye disorder (“DED”) accredited from researchers at On Goal Therapeutics LLC.  OKYO has formerly introduced that it anticipates making an investigational new drug submission with the US Food stuff and Drug Administration for the use of chemerin in the cure of DED.

“Collectively with On Focus on Therapeutics LLC, we have been checking out chemerin and associated analogues for other potential therapeutic makes use of and are now also focusing on chemerin as a novel tactic to treating COVID-19 and ARDS sufferers,” mentioned Dr. Gary S. Jacob, CEO of OKYO. “We are doing work aggressively to grow this COVID-19 work and will be furnishing development on this challenge as critical developments manifest.”

Dr. Napoleone Ferrara, a member of OKYO’s Scientific Advisory Board, will be spearheading this energy at OKYO to progress chemerin and its related analogues for the treatment of patients with SARS-CoV-2 virus and ARDS. Dr. Ferrara, winner of the prestigious Lasker award and a member of the Countrywide Academy of Sciences United states, was the scientist who isolated vascular endothelial growth aspect (VEGF), a discovery that led to the two blockbuster medication Lucentis® and Avastin® (which together accounted for more than US$9 billion in gross sales in 2019) as well as to the class of anti-VEGF medication, which are widely employed to treat cancer and intraocular neovascular conditions.

Dr. Ferrara commented: “We are pretty thrilled to be performing with our collaborating business and academic associates to produce this promising addition to the COVID-19 therapeutic armamentarium and, of program, to expedite analysis in people as quickly as achievable. Outside of COVID-19, chemerin, which is a perfectly-proven modulator of irritation, has assure for managing ARDS, a pathological affliction that may be brought on by a host of insults to the lungs (e.g., pneumonia, sepsis, pancreatitis and inhalation injuries).”

About Chemerin and its receptor: The chemerin receptor (“CMKLR1”, also recognised as ChemR23) is a chemokine like G protein-coupled receptor (“GPCR”) expressed on pick populations of cells, like inflammatory mediators (including macrophages, monocytes, plasmacytoid/myeloid dendritic cells and pure killer cells), as properly as epithelial cells.  Activation of CMKLR1 by its endogenous peptide ligand chemerin is identified to modulate inflammation, but natural ligands for CMKLR1 have limited fifty percent-lives because of to quick inactivation.  Discovery of a secure, superior efficiency CMKLR1 agonist (secure lipidated chemerin) by On Focus on Therapeutics LLC supplied an essential phase towards the development of a new course of anti-inflammatory therapeutics.

The man or woman who arranged for the launch of this announcement on behalf of the Business was Dr. Gary S. Jacob, Chief Executive Officer of OKYO.

 

Enquiries:

OKYO Pharma Limited

Gary S. Jacob, Chief Government Officer

Gabriele Cerrone, Non-Government Chairman

+44 ()20 7495 2379

 

 

 

Optiva Securities Minimal
(Broker)

Robert Emmet

+44 ()20 3981 4173

 

 

 

RedChip Businesses Inc.
(Trader Relations)

Dave Gentry

[email protected]

+1 407-491-4498

 

Notes for Editors:

About OKYO

OKYO Pharma Limited (LSE: OKYO OTCQB: EMMLF) is a daily life sciences and biotechnology firm admitted to listing on the normal phase of the Official Checklist of the Uk Fiscal Carry out Authority and to trading on the most important market place for detailed securities of London Stock Exchange plc. OKYO is concentrating on the discovery and improvement of novel molecules to address inflammatory dry eye health conditions and continual ache.

About Dr. Napoleone Ferrara

Dr. Ferrara is a member of The Countrywide Academy of Sciences and has been given numerous prestigious awards, including the Lasker Award and the Breakthrough Prize in Life Sciences. His study on comprehension the function of angiogenesis and vascular endothelial advancement component (VEGF) in most cancers progress, led to the discovery that VEGF is a vital mediator of angiogenesis associated with intraocular neovascular syndromes. This groundbreaking investigate led to the clinical development of a humanized anti-VEGF Fab (Ranibizumab, Lucentis®), which has also been accepted as a remedy for neovascular age-relevant macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. Ranibizumab and other anti-VEGF agents have experienced a remarkable affect on the improvement of therapies for these blinding problems. When Lucentis® (Ranibizumab) received Fda approval in late June 2006, the new macular degeneration drug was celebrated as a important health care breakthrough. Dr. Ferrara’s exploration also led to the advancement and acceptance of humanized anti-VEGF mAbs (Bevacizumab Avastin®) for cancer therapy, with Avastin® remaining 1 of the bestselling most cancers medications above the final two many years. Lucentis® and Avastin® collectively achieved in excess of $9 billion in sales in 2019.

.

Forward-Seeking Statements:

Specified statements produced in this announcement are forward-hunting statements. These ahead-searching statements are not historic specifics but alternatively are dependent on the Company’s latest anticipations, estimates, and projections about its sector its beliefs and assumptions. Words these as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and very similar expressions are supposed to determine ahead-looking statements. These statements are not assures of future performance and are subject to acknowledged and unknown challenges, uncertainties, and other aspects, some of which are over and above the Company’s management, are hard to forecast, and could trigger precise final results to vary materially from those expressed or forecasted in the forward-on the lookout statements. The Company cautions safety holders and possible protection holders not to area undue reliance on these ahead-searching statements, which reflect the perspective of the Company only as of the day of this announcement. The ahead-searching statements created in this announcement relate only to gatherings as of the day on which the statements are built. The Company will not undertake any obligation to release publicly any revisions or updates to these ahead-searching statements to reflect gatherings, conditions, or unanticipated events developing after the day of this announcement except as demanded by regulation or by any correct regulatory authority.

For even more facts, please check out the Firm’s internet site at www.okyopharma.com.